Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19254545 | 0.94 | METAP2 (0.78) | METAP2 | |
| SCHEMBL12037940 | 0.92 | METAP2 (0.84) | METAP2 | |
| SCHEMBL21017472 | 0.91 | METAP2 (0.83) | METAP2 | |
| SCHEMBL3988213 | 0.90 | METAP2 (1.00) | METAP2 | |
| SCHEMBL3986694 | 0.90 | METAP2 (1.00) | METAP2 | |
| SCHEMBL3986691 | 0.90 | METAP2 (1.00) | METAP2 | |
| SCHEMBL19880254 | 0.89 | METAP2 (0.81) | METAP2 | |
| SCHEMBL16176014 | 0.89 | METAP2 (1.00) | METAP2 | |
| SCHEMBL3979227 | 0.85 | METAP2 (1.00) | METAP2 | |
| SCHEMBL3982013 | 0.85 | METAP2 (1.00) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210077452-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10722532-B2 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200155545-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10646463-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20160184345-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9320805-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150374657-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9173956-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20140308235-A1 | METAP2 Inhibitors and Methods of Treating Obesity | SYNDEVRX, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130216494-A1 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof | SynDecRx, Inc. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20110294952-A1 | Optimized Drug Conjugates | SynDevRX (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011150022-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184345-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885 |
| US-20110294952-A1 | Optimized Drug Conjugates | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885 |
| US-20140308235-A1 | METAP2 Inhibitors and Methods of Treating Obesity | METAP2, ADIPOR2, METAP1 | METAP2 1/4885 |
| US-20130216494-A1 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof | METAP2, MTX2, METAP1 | METAP2 1/4885 |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885 |
| US-10646463-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | METAP2 40/4885 |
| US-10722532-B2 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof | METAP2, MTX2, METAP1 | METAP2 1/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | METAP2 1/4885 |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885 |
| US-20200155545-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885 |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885 |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885 |
| US-20210077452-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | PCK2, GOT2, PC | METAP2 40/4885 |
| US-20150374657-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.